CD Biosynsis offers comprehensive solutions to unlock the full potential of Pseudomonas putida as a premier microbial cell factory. P. putida is highly valued in industrial biotechnology due to its exceptional robustness, high-yield capabilities under aerobic conditions, and natural tolerance to organic solvents and harsh environments. Our integrated platform spans the entire strain development pipeline, connecting precision genome editing with predictive metabolic engineering and automated screening. We provide end-to-end services, from constructing a minimal chassis strain and optimizing complex biosynthetic pathways to delivering high-purity recombinant proteins, ensuring rapid, rational, and scalable development of high-performance P. putida strains for sustainable biomanufacturing and bioremediation applications.
Get a QuoteSuccessfully engineering P. putida for industrial use requires a multidisciplinary approach that moves beyond simple trial-and-error. Our platform is built on the iterative Design-Build-Test-Learn (DBTL) cycle, ensuring that every genetic modification is guided by quantitative data and predictive models. We utilize the latest advancements in synthetic biology, including scarless CRISPR-Cas9 editing for permanent changes, CRISPRi for expression fine-tuning, and robust computational modeling to accurately forecast metabolic flux. This integration drastically reduces R&D timelines, minimizes the need for iterative experiments, and ensures the resulting strains are genetically stable and phenotypically optimized for large-scale production demands.
Core Technology
Includes Multi-Gene Knockout Construction, CRISPR-Cas9 for knock-ins, CRISPRi for repression, and Base Editing for precise SNPs.
Goal
To create a streamlined, marker-free chassis strain by deleting competitive pathways and stably integrating synthetic genes into the genome.
Core Tools
Relies on Assay & Modeling Services (FBA and MCA) combined with metabolomics to identify and alleviate systemic bottlenecks.
Strategy
Fine-tuning gene expression ratios, enhancing precursor supply, optimizing cofactor regeneration, and improving tolerance to toxic intermediates.
Screening
Automated HTS using microplate assays, robotics, and biosensors for rapid screening of thousands of strain variants.
Deliverables
Delivering optimized strains or high-purity product via Protein Expression & Purification Services, ensuring stable, active product delivery.
Our modular service architecture allows clients to engage at any stage of the strain engineering lifecycle, from initial design to final product purification.
1. Computational Design
2. Precision Editing
3. Optimization & Testing
4. Product Delivery
Utilizing FBA and Kinetic Modeling to predict optimal genetic edits and fermentation conditions. This phase generates the rational design plan.
Executing targeted modifications (Knockout, Knock-in, Base Editing) to construct the new strain variants precisely and efficiently.
High-Throughput Screening (HTS) and iterative refinement (DBTL) combined with fluxomics to maximize performance metrics (titer, yield, productivity).
Delivering the final optimized strain or, if required, proceeding to high-yield protein expression, purification, and quality control.
Bioproduction of Fine Chemicals
Engineering P. putida for the high-yield production of high-value compounds such as terpenoids, aromatic chemicals, and precursors for polymers.
Sustainable Bioremediation
Enhancing P. putida's native degradation pathways for the efficient breakdown of environmental pollutants, including plastics and xenobiotics.
Protein and Enzyme Production
Leveraging P. putida's robust aerobic system for high-quality, soluble expression and purification of complex, redox-dependent enzymes like P450s.
Advanced Biopolymers & Materials
Developing engineered strains for the biosynthesis of advanced biopolymers (e.g., PHAs) and other renewable materials from sustainable feedstocks.
How does the integrated platform shorten the development timeline?
By using predictive modeling (Design) to generate rational hypotheses before expensive experiments, and by employing automated HTS (Test) and multiplex editing (Build), we drastically reduce the number of necessary experimental iterations (DBTL cycle).
Is P. putida suitable for anaerobic processes?
No. P. putida is primarily an aerobic organism. Its high production efficiency is fundamentally linked to its robust respiratory system, making it best suited for aerobic or microaerobic biomanufacturing processes.
Do you guarantee the final strain will be stable?
Yes. We ensure stability by relying on stable genomic integration (knock-in) rather than unstable plasmids, confirming scarless modifications, and performing final stability checks through Adaptive Laboratory Evolution (ALE) and prolonged culture tests.
What are the key deliverables for a complete optimization project?
Deliverables include the final optimized, validated P. putida strain, comprehensive data on final product titer, yield, and productivity, the validated computational model file, and a detailed engineering and data analysis report.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
|
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.